share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股sec公告 ·  05/16 12:36
Moomoo AI 已提取核心訊息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number...Show More
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has filed an amendment to its Form 8-K with the U.S. Securities and Exchange Commission. The amendment, dated May 15, 2024, clarifies details regarding the company's previously announced reverse stock split. The amendment specifies that only the company's common stock, not its public warrants, will begin trading on a split-adjusted basis at the market open on May 17, 2024. Additionally, equitable adjustments will be made to the outstanding warrants in accordance with the reverse stock split ratio. The reverse stock split will convert every one hundred shares of the pre-split common stock into one post-split share, with all fractional shares rounded up. The new CUSIP number for the common stock will be 42254E302 post-split. The exercise price for the public warrants will be adjusted to $425.00 per share, reflecting the reverse split ratio. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively, although the CUSIP for the public warrants will not change.
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 已向美國證券交易委員會提交了其8-K表的修正案。該修正案於2024年5月15日發佈,澄清了有關該公司先前宣佈的反向股票拆分的細節。該修正案規定,只有公司的普通股,而不是其公開認股權證,將在2024年5月17日開盤時開始按拆分調整後的基礎上交易。此外,將根據反向股票分割比率對未償還的認股權證進行公平調整。反向股票拆分將把拆分前普通股的每一百股轉換爲拆分後的一股,所有零星股票四捨五入。拆分後,普通股的新CUSIP號碼將爲 42254E302。公開認股權證的行使價將調整爲每股425.00美元,反映反向拆分比率。儘管公開認股權證的CUSIP不會改變,但普通股和公開認股權證的交易代碼將分別保持爲 “HSCS” 和 “HSCSW”。
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 已向美國證券交易委員會提交了其8-K表的修正案。該修正案於2024年5月15日發佈,澄清了有關該公司先前宣佈的反向股票拆分的細節。該修正案規定,只有公司的普通股,而不是其公開認股權證,將在2024年5月17日開盤時開始按拆分調整後的基礎上交易。此外,將根據反向股票分割比率對未償還的認股權證進行公平調整。反向股票拆分將把拆分前普通股的每一百股轉換爲拆分後的一股,所有零星股票四捨五入。拆分後,普通股的新CUSIP號碼將爲 42254E302。公開認股權證的行使價將調整爲每股425.00美元,反映反向拆分比率。儘管公開認股權證的CUSIP不會改變,但普通股和公開認股權證的交易代碼將分別保持爲 “HSCS” 和 “HSCSW”。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息